三個皮匠報告
政策庫
new
付費
搜索

全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）-行業數據

全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）
鑒于 GLP-1、GCG、GIP、FGFR 的代謝調控作用，且相互之間具有鮮明的協同作用，因此多個醫藥公司也開始研發 GLP-1、GCG、GIP、FGFR 等多靶點受體激動劑。
行業數據 下載Excel 下載圖片 原圖定位
圖片屬性
圖片格式：PNG 圖片大?。?18KB 圖片尺寸：2281*645
同報告圖片
 / 48
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第1頁
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
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第2頁
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第3頁
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第4頁
fCDlubTku70gfCDlhajnkIPlpJrogr3oja/nianluILlnLrop4TmqKHvvIjkur/nvo7lhYPvvIkgfCBZT1kgfAp8LS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tfC0tLS0tLXwKfCAyMDE2IHwgNTAwICAgICAgICAgICAgICAgICAgICAgICAgIHwgNiUgICB8CnwgMjAxNyB8IDU1MCAgICAgICAgICAgICAgICAgICAgICAgICB8IDEwJSAgfAp8IDIwMTggfCA2MDAgICAgICAgICAgICAgICAgICAgICAgICAgfCA5JSAgIHwKfCAyMDE5IHwgNjUwICAgICAgICAgICAgICAgICAgICAgICAgIHwgOCUgICB8CnwgMjAyMCB8IDcwMCAgICAgICAgICAgICAgICAgICAgICAgICB8IDklICAgfAp8IDIwMjFFfCA4MDAgICAgICAgICAgICAgICAgICAgICAgICAgfCAxNCUgIHwKfCAyMDIyRXwgOTAwICAgICAgICAgICAgICAgICAgICAgICAgIHwgMTIlICB8CnwgMjAyM0V8IDEwMDAgICAgICAgICAgICAgICAgICAgICAgICB8IDExJSAgfAp8IDIwMjRFfCAxMTAwICAgICAgICAgICAgICAgICAgICAgICAgfCAxMCUgIHwKfCAyMDI1RXwgMTIwMCAgICAgICAgICAgICAgICAgICAgICAgIHwgOSUgICB8CnwgMjAyNkV8IDEzMDAgICAgICAgICAgICAgICAgICAgICAgICB8IDglICAgfAp8IDIwMjdFfCAxNDAwICAgICAgICAgICAgICAgICAgICAgICAgfCA3JSAgIHwKfCAyMDI4RXwgMTUwMCAgICAgICAgICAgICAgICAgICAgICAgIHwgNyUgICB8CnwgMjAyOUV8IDE2MDAgICAgICAgICAgICAgICAgICAgICAgICB8IDclICAgfAp8IDIwMzBFfCAxNzAwICAgICAgICAgICAgICAgICAgICAgICAgfCA2JSAgIHwKCui1hOaWmeadpea6kO+8mue7tOW6pue6teaoquWFrOS8l+WPt++8jOW8l+e9l+aWr+eJueaymeWIqeaWh++8jOWkqemjjuivgeWIuOeglOeptuaJgA==
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第5頁
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
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第6頁
5qC55o2u5Zu+54mH5Lit55qE5pWw5o2u77yM5Lul5LiL5piv55Sf5oiQ55qE6KGo5qC877yaCgp8IOW5tOS7vSB8IE1lbiB8IFdvbWVuIHwgQm95cyB8IEdpcmxzIHwKfC0tLS0tLXwtLS0tLXwtLS0tLS0tfC0tLS0tLXwtLS0tLS0tfAp8IDIwMjAgfCAxMCUgfCA3JSAgICB8IDIwJSAgfCAxMCUgICB8CnwgMjAyNSB8IDE1JSB8IDEwJSAgIHwgMzAlICB8IDE1JSAgIHwKfCAyMDMwIHwgMjAlIHwgMTIlICAgfCA0MCUgIHwgMjAlICAgfAp8IDIwMzUgfCAyNSUgfCAxNSUgICB8IDUwJSAgfCAyNSUgICB8CgrotYTmlpnmnaXmupDvvJrjgIpXb3JsZCBPYmVzaXR5IEF0bGFzIDIwMjMgUmVwb3J044CL77yM5aSp6aOO6K+B5Yi456CU56m25omA
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第7頁
5qC55o2u5Zu+54mH5Lit55qE5pWw5o2u77yM5Lul5LiL5piv55Sf5oiQ55qE6KGo5qC877yaCgp8IOW5tOS7vSB8IE1lbiB8IFdvbWVuIHwgQm95cyB8IEdpcmxzIHwKfC0tLS0tLXwtLS0tLXwtLS0tLS0tfC0tLS0tLXwtLS0tLS0tfAp8IDIwMjAgfCAxNCUgfCAxOSUgICB8IDExJSAgfCA5JSAgICB8CnwgMjAyNSB8IDE2JSB8IDIxJSAgIHwgMTMlICB8IDExJSAgIHwKfCAyMDMwIHwgMTklIHwgMjQlICAgfCAxNiUgIHwgMTQlICAgfAp8IDIwMzUgfCAyMiUgfCAyNyUgICB8IDE5JSAgfCAxNyUgICB8CgrotYTmlpnmnaXmupDvvJrjgIpXb3JsZCBPYmVzaXR5IEF0bGFzIDIwMjMgUmVwb3J044CL77yM5aSp6aOO6K+B5Yi456CU56m25omA
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第8頁
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第9頁
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
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第10頁
fCBVQjEyNTHkuI5SZXRhdHJ1dGlkZeWcqERJTyBtaWNl55qE5YeP6YeN5pWI5p6c5a+55q+UIHwgQm9keSB3ZWlnaHQgY2hhbmdlICglKSB8IAp8LS0tfC0tLXwgCnwgVmVoaWNsZSB8IC0yLjc1JSB8IAp8IFVCMTI1MSAzIG5tb2wva2cgfCAtMzYuNDQlIHwgCnwgVUIxMjUxIDEwIG5tb2wva2cgfCAtNDcuNTclIHwgCnwgUmV0YXRydXRpZGUgMyBubW9sL2tnIHwgLTI3LjY0JSB8IAp8IFJldGF0cnV0aWRlIDEwIG5tb2wva2cgfCAtNDQuMjUlIHwgCui1hOaWmeadpea6kO+8muiBlOmCpuWItuiNr+aOqOS7i+adkOaWme+8jOWkqemjjuivgeWIuOeglOeptuaJgA==
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第11頁
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
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第12頁
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第13頁
fCDnsbvliKsgICAgICAgfCAyMDIy5bm0IHwgMjAyM+W5tCB8IDIwMjTlubQgfAp8LS0tLS0tLS0tLS0tfC0tLS0tLS0tfC0tLS0tLS0tfC0tLS0tLS0tfAp8IOiDsOWym+e0oOazqOWwhOeslCB8IDkuOCAgICB8IDUuNyAgICB8IDI4LjkgICB8Cnwg6Zeo5Yas6IOw5bKb57SgICAgfCA5MS42ICAgfCAxODguNCAgfCAyNTAuMyAgfAp8IOeUmOeyvuiDsOWym+e0oCAgIHwgNDIyLjIgIHwgNDIyLjUgIHwgNDk5LjUgIHwKfCDph43nu4Tkurrog7DlspvntKAgfCA2NjEuOCAgfCA1MDYuNiAgfCA0NTcuNiAgfAoK6LWE5paZ5p2l5rqQ77ya5YWs5Y+45o6o5LuL5p2Q5paZ77yM5aSp6aOO6K+B5Yi456CU56m25omA
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第14頁
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
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第15頁
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
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第16頁
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
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第17頁
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第18頁
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第19頁
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第20頁
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第21頁
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
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第22頁
5Lul5LiL5piv5qC55o2u5oKo5o+Q5L6b55qE5Zu+54mH55Sf5oiQ55qE5pWw5o2u6KGo5qC877yaCgp8IOeOieexs+WPkemFtSDihpIg6Z2S6ZyJ57Sg5bel5Lia55uQIOKGkiDlhYvmi4nnu7Tphbjpkr4gJiDlk4zmi4nopb/mnpcgJiDpnZLpnInntKDpkr4gJiDpnZLpnInntKDpkqAgfAp8IC0tLSB8CnwgNi1BUEEg4oaSIOmYv+iOq+ilv+aelyAmIOawqOiLhOilv+aelyAmIOabv+WNoeilv+aelyAmIOe+jue9l+WfueWNlyB8CgrotYTmlpnmnaXmupDvvJrkuK3lm73lhb3oja/ppbLmlpnkuqTmmJPkuK3lv4PlhazkvJflj7fvvIzlpKnpo47or4HliLjnoJTnqbbmiYA=
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第23頁
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
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第24頁
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
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第25頁
5Lul5LiL5piv5o+Q5Y+W55qE5pWw5o2u5bm255Sf5oiQ55qE6KGo5qC877yaCgp8IOaXpeacnyAgICAgICB8IDYtQVBB5Ye65Y+j5bmz5Z2H5Y2V5Lu377yI576O5YWDL+WNg+WFi++8iSB8CnwtLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS18CnwgMjAyMy0wMSAgICB8IDM1LjAwICAgICAgICAgICAgICAgICAgICAgICB8CnwgMjAyMy0wMyAgICB8IDM0LjUwICAgICAgICAgICAgICAgICAgICAgICB8CnwgMjAyMy0wNSAgICB8IDMzLjAwICAgICAgICAgICAgICAgICAgICAgICB8CnwgMjAyMy0wNyAgICB8IDMyLjUwICAgICAgICAgICAgICAgICAgICAgICB8CnwgMjAyMy0wOSAgICB8IDMzLjAwICAgICAgICAgICAgICAgICAgICAgICB8CnwgMjAyMy0xMSAgICB8IDMyLjAwICAgICAgICAgICAgICAgICAgICAgICB8CnwgMjAyNC0wMSAgICB8IDMxLjUwICAgICAgICAgICAgICAgICAgICAgICB8CnwgMjAyNC0wMyAgICB8IDMxLjAwICAgICAgICAgICAgICAgICAgICAgICB8CnwgMjAyNC0wNSAgICB8IDMwLjUwICAgICAgICAgICAgICAgICAgICAgICB8CnwgMjAyNC0wNyAgICB8IDMwLjAwICAgICAgICAgICAgICAgICAgICAgICB8CnwgMjAyNC0wOSAgICB8IDI5LjUwICAgICAgICAgICAgICAgICAgICAgICB8CnwgMjAyNC0xMSAgICB8IDI5LjAwICAgICAgICAgICAgICAgICAgICAgICB8CnwgMjAyNS0wMSAgICB8IDI4LjUwICAgICAgICAgICAgICAgICAgICAgICB8CgrotYTmlpnmnaXmupDvvJpXaW5k77yM5aSp6aOO6K+B5Yi456CU56m25omA
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第26頁
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
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第27頁
fCDml6XmnJ8gfCDlh7rlj6PlubPlnYfljZXku7fvvIjnvo7lhYMv5Y2D5YWL77yJIHwKfC0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwKfCAyMDA3LTAxIHwgMzAuMDAgICAgICAgICAgICAgICAgICAgIHwKfCAyMDA3LTAyIHwgMzUuMDAgICAgICAgICAgICAgICAgICAgIHwKfCAyMDA3LTAzIHwgNDAuMDAgICAgICAgICAgICAgICAgICAgIHwKfCAuLi4gICAgfCAuLi4gICAgICAgICAgICAgICAgICAgICAgfAp8IDIwMjQtMDcgfCAzMC4wMCAgICAgICAgICAgICAgICAgICAgfAoK6LWE5paZ5p2l5rqQ77yaV2luZO+8jOWkqemjjuivgeWIuOeglOeptuaJgA==
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第28頁
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
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第29頁
fCDluILlnLogfCDph5Hpop3vvIjkur/lhYPvvIkgfAp8LS0tLS0tfC0tLS0tLS0tLS0tLXwKfCDkuK3lm70gIHwgNjMuODggICAgICB8Cnwg5qyn5rSyICB8IDYuOTYgICAgICAgfAp8IOWNsOW6piAgfCA2LjM0ICAgICAgIHwKfCDkuK3kuJwgIHwgNy4zMyAgICAgICB8Cnwg5Y2X576O5rSyIHwgMy42MyAgICAgICB8Cnwg5YW25LuW5Lqa5rSy5Zyw5Yy6IHwgNi4zMyAgICAgIHwKfCDlhbbku5blnLDljLogfCAyLjQ0ICAgICAgIHwKCui1hOaWmeadpea6kO+8muiBlOmCpuWItuiNr+aOqOS7i+adkOaWme+8jOWkqemjjuivgeWIuOeglOeptuaJgA==
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第30頁
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第31頁
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第32頁
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第33頁
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第34頁
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第35頁
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第36頁
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第37頁
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第38頁
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第39頁
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第40頁
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第41頁
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第42頁
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第43頁
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第44頁
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
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第45頁
5aW955qE77yM5Lul5LiL5piv5oKo5Zu+54mH5Lit55qE5pWw5o2u6KGo5qC877yaCgp8IOWVhuWTgeWQjSAgICAgICAgICB8IOaIkOWIhuivjSAgICAgICAgICAgfCDkvIHkuJogICB8IDIwMjDlubQgfCAyMDIx5bm0IHwgMjAyMuW5tCB8IDIwMjPlubQgfCAyMDI05bm0IHwKfC0tLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLXwtLS0tLS0tLS18LS0tLS0tLS0tfC0tLS0tLS0tLXwtLS0tLS0tLS18LS0tLS0tLS0tfAp8IE96ZW1waWMvV2Vnb3Z5ICB8IOWPuOe+jumygeiCve+8iOazqOWwhO+8iSB8IOivuuWSjOivuuW+tyB8IDMyLjY0ICAgfCA1NS42NiAgIHwgOTMuMzAgICB8IDE4NC40OSAgfCAyNTguMzYgIHwKfCBNb3VuamFyby9aZXBib3VuZCB8IOiRm+WwlOaziuiCvSAgICAgICB8IOekvOadpeWItuiNryB8ICAgICAgICAgfCAgICAgICAgIHwgNC44MyAgICB8IDUzLjM5ICAgfCAxNjQuNjYgIHwKfCBUcnVsaWNpdHkgICAgICAgIHwg5bqm5ouJ57OW6IK9ICAgICAgICAgfCDnpLzmnaXliLboja8gfCA1MC42OCAgIHwgNjQuNzIgICB8IDc0LjQwICAgfCA3MS4zMyAgIHwgNTIuNTQgICB8CnwgUnliZWxzdXMgICAgICAgIHwg5Y+4576O6bKB6IK977yI5Y+j5pyN77yJIHwg6K+65ZKM6K+65b63IHwgMi44OCAgICB8IDcuNjcgICAgfCAxNS45OSAgIHwgMjcuMjMgICB8IDMzLjcyICAgfAp8IFZpY3RvemEvU2F4ZW5kYSB8IOWIqeaLiemygeiCvSAgICAgICAgIHwg6K+65ZKM6K+65b63IHwgMzcuNDggICB8IDM1LjAwICAgfCAzMi41NSAgIHwgMjcuNTIgICB8IDE3Ljk3ICAgfAoK6LWE5paZ5p2l5rqQ77yaSW5zaWdodOaVsOaNruW6k++8jOWkqemjjuivgeWIuOeglOeptuaJgA==
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第46頁
5qC55o2u5oKo5o+Q5L6b55qE5Zu+54mH5YaF5a6577yM5Lul5LiL5piv5pWw5o2u6KGo5qC85ZKM6LWE5paZ5p2l5rqQ77yaCgp8IOWcsOWMuiB8IOWIqeaLiemygeiCvSB8IOWPuOe+jumygeiCvSB8IOabv+WwlOaziuiCvSB8CnwtLS0tLS18LS0tLS0tLS0tLXwtLS0tLS0tLS0tfC0tLS0tLS0tLS18Cnwg5Lit5Zu9IHwg5bey5Yiw5pyfICAgfCAyMDI25bm0ICAgfCAyMDM25bm0ICAgfAp8IOe+juWbvSB8IOW3suWIsOacnyAgIHwgMjAzMuW5tCAgIHwgMjAzNuW5tCAgIHwKCui1hOaWmeadpea6kO+8mkluc2lnaHTmlbDmja7lupPvvIzlpKnpo47or4HliLjnoJTnqbbmiYA=
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第47頁
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
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第48頁
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
全球主要三（及以上）靶點GLP-1類藥物減重臨床進度（截至2025/4/2）_第49頁
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
所屬報告： 聯邦制藥-港股公司研究報告-UBT251已授權給諾和諾德動保胰島素穩健增長-250520（33頁）.pdf
打包全文圖表

相關數據

最新數據
聯系我們
  • 0731-84720580
  • sgpjbg002
  • 工作日 9:30 - 18:00
關于我們
侵權處理
關于我們

三個皮匠報告專業的行業報告下載站，每日更新，歡迎大家關注！

copyright@2008-2013 長沙景略智創信息技術有限公司版權所有
網站備案/許可證號：湘B2-20190120

客服
商務合作
小程序
服務號
折疊
午夜网日韩中文字幕,日韩Av中文字幕久久,亚洲中文字幕在线一区二区,最新中文字幕在线视频网站